

Cover Story
Regulatory News
By Jacquelyn Cobb and Paul Goldberg
The FDA Oncologic Drugs Advisory Committee voted overwhelmingly in favor of expanding the indications of two chimeric antigen receptor engineered T-cell therapies for multiple myeloma that showed improvement in progression-free survival, but also reported a higher number of early deaths on the experimental arm.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - Bhattacharya: New grant review criterion is “not political”
- Population-based cancer surveillance is a national treasure at risk
- With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shut down
- Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence